Research Access Portal
Every compound synthesized, lyophilized, and independently tested right here in the United States — with a public COA on every single batch.
Made in the USA
Zero overseas shortcuts
Batch Tested, Batch Produced
HPLC + LC-MS on every batch
Public COA Vault
Linked on every product page
38+ Compounds
GLP-1, peptides, longevity & more
© 2026 Aldera Bio Labs
This site is for individuals 21 or older purchasing strictly for laboratory research purposes.
By entering, you confirm you are at least 21 years old and understand all products are sold strictly for research use only — not for human or veterinary consumption.
Aldera Bio Labs • USA Access • Research Use Only
Research Catalog
A complete reference index of every research peptide and compound in the Aldera Bio Labs catalog — including mechanism of action, receptor targets, research focus areas, purity, and available formats. All compounds are third-party tested by Horizon Analytical with COA Vault documentation on every batch.
Showing 35 of 35 compounds
Also known as: Ozempic analog · GLP-1 RA
Mechanism of Action
GLP-1 receptor agonist — activates GLP-1R via cAMP/PKA signaling to suppress glucagon, delay gastric emptying, and modulate hypothalamic satiety circuits.
Research Focus
Metabolic regulation, insulin secretion, body weight homeostasis, cardiovascular risk markers.
Also known as: GIP/GLP-1 dual agonist · Mounjaro analog
Mechanism of Action
Dual GIP/GLP-1 receptor agonist — simultaneous activation of GIPR and GLP-1R produces additive effects on insulin secretion, glucagon suppression, and energy expenditure.
Research Focus
Dual incretin signaling, adipose tissue metabolism, beta-cell function, weight regulation.
Also known as: GIP/GLP-1/glucagon triple agonist
Mechanism of Action
Triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously — adds hepatic glucagon signaling to the dual incretin mechanism for enhanced energy expenditure.
Research Focus
Triple receptor pharmacology, hepatic lipid metabolism, energy homeostasis, obesity research.
Also known as: AM833 · amylin analog
Mechanism of Action
Long-acting acylated amylin receptor agonist — non-selective agonist of AMY1R, AMY2R, AMY3R, and CTR with C20 fatty acid chain for extended half-life via albumin binding.
Research Focus
Amylin receptor pharmacology, satiety signaling, combination metabolic research (CagriSema).
Also known as: GHRH 1-29 · GRF 1-29
Mechanism of Action
Selective GHRH receptor agonist — binds somatotrophs in the anterior pituitary and activates adenylate cyclase-cAMP signaling to trigger pulsatile GH release.
Research Focus
Pituitary somatotroph function, pulsatile GH secretion, hypothalamic-pituitary axis.
Also known as: GHSR agonist · ghrelin mimetic
Mechanism of Action
Selective ghrelin/GHSR-1a receptor agonist — stimulates GH release without significant cortisol, prolactin, or ACTH elevation, making it highly selective among GH secretagogues.
Research Focus
Selective GH secretagogue pharmacology, GHSR receptor binding, GH pulse amplitude.
Also known as: Modified GRF 1-29 · Mod GRF
Mechanism of Action
GHRH analog with four amino acid substitutions for protease resistance — short half-life (~30 min) produces physiological pulsatile GH release when dosed with a GHSR agonist.
Research Focus
Pulsatile GH secretion, GHRH receptor pharmacology, synergistic GH secretagogue combinations.
Also known as: DAC:GRF
Mechanism of Action
GHRH analog with Drug Affinity Complex (DAC) — covalently binds to serum albumin via a maleimide linker, extending half-life to 6–8 days and producing sustained GH elevation.
Research Focus
Extended-release GHRH pharmacology, albumin-binding drug delivery, sustained GH secretion.
Also known as: Growth Hormone-Releasing Peptide 6
Mechanism of Action
Synthetic hexapeptide GHSR-1a agonist — stimulates GH release and also activates ghrelin-mediated appetite signaling via the hypothalamic arcuate nucleus.
Research Focus
GHSR pharmacology, appetite regulation, GH/IGF-1 axis, ghrelin receptor biology.
Also known as: Ibutamoren · L-163,191
Mechanism of Action
Orally active, non-peptide GHSR-1a agonist — mimics ghrelin to stimulate GH and IGF-1 secretion with a long half-life (~24 hours) suitable for once-daily dosing in research models.
Research Focus
Oral GH secretagogue pharmacology, IGF-1 axis, sleep architecture, muscle catabolism research.
Also known as: Body Protection Compound 157 · PL 14736
Mechanism of Action
Pentadecapeptide derived from human gastric juice — promotes angiogenesis via VEGFR2 upregulation, modulates nitric oxide synthesis, and activates FAK-paxillin signaling in fibroblast migration.
Research Focus
Tissue repair, angiogenesis, gut mucosal healing, tendon and ligament research, NO pathway modulation.
Also known as: Thymosin Beta-4 fragment · Tβ4 fragment
Mechanism of Action
Synthetic fragment of Thymosin Beta-4 — sequesters G-actin monomers via LKKTET motif to regulate actin polymerization, promotes cell migration, and upregulates anti-inflammatory cytokines.
Research Focus
Actin dynamics, cell migration, wound healing, cardiac repair, anti-inflammatory signaling.
Also known as: BPC-157/TB-500 combination
Mechanism of Action
Combination of BPC-157 and TB-500 in a single lyophilized formulation — targets complementary repair pathways: VEGFR2/NO signaling (BPC-157) and actin/cell migration (TB-500).
Research Focus
Synergistic tissue repair research, dual-pathway healing models, angiogenesis + actin dynamics.
Also known as: Bremelanotide
Mechanism of Action
Melanocortin receptor agonist — activates MC3R and MC4R in the hypothalamus and limbic system, modulating dopaminergic and serotonergic pathways involved in sexual arousal research.
Research Focus
MC3R/MC4R pharmacology, central nervous system melanocortin signaling, sexual function research.
Also known as: MT-II · alpha-MSH analog
Mechanism of Action
Non-selective melanocortin receptor agonist — activates MC1R through MC5R with high potency, affecting pigmentation (MC1R), sexual function (MC3R/MC4R), and energy homeostasis (MC4R).
Research Focus
Melanocortin receptor pharmacology, pigmentation biology, energy balance, appetite suppression.
Also known as: Afamelanotide analog · alpha-MSH analog
Mechanism of Action
Selective MC1R agonist — targets melanocyte-stimulating hormone receptor 1 to stimulate eumelanin production in melanocytes with greater selectivity than MT-2.
Research Focus
MC1R selective pharmacology, melanogenesis, photoprotection research, pigmentation biology.
Also known as: Metastin · KiSS-1 peptide
Mechanism of Action
Endogenous neuropeptide that activates the KISS1R (GPR54) receptor — acts as a master regulator of the hypothalamic-pituitary-gonadal axis by stimulating GnRH pulse release.
Research Focus
HPG axis regulation, GnRH pulse generation, reproductive endocrinology, puberty onset research.
Also known as: TP-7 · tuftsin analog
Mechanism of Action
Synthetic heptapeptide analog of tuftsin — modulates GABAergic transmission, upregulates BDNF expression, and inhibits enkephalin-degrading enzymes to prolong endogenous opioid activity.
Research Focus
Anxiolytic mechanisms, GABAergic modulation, BDNF upregulation, HPA axis stress response.
Also known as: ACTH(4-7)PGP · MEHFPGP
Mechanism of Action
Synthetic heptapeptide derived from ACTH(4-7) — upregulates BDNF and NGF expression, activates melanocortin receptors, and modulates dopaminergic and serotonergic neurotransmission.
Research Focus
Neuroprotection, BDNF/NGF upregulation, cognitive function research, stroke recovery models.
Also known as: Epitalon · Epithalamin tetrapeptide
Mechanism of Action
Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from Epithalamin — activates telomerase (hTERT) expression, regulates melatonin secretion via the pineal gland, and modulates antioxidant enzyme activity.
Research Focus
Telomerase activation, telomere elongation, pineal gland function, cellular aging research.
Also known as: Delta Sleep-Inducing Peptide
Mechanism of Action
Endogenous neuropeptide — modulates delta-wave sleep architecture, attenuates HPA axis stress responses, and interacts with opioid and somatostatin receptor systems.
Research Focus
Sleep architecture, delta-wave EEG modulation, HPA axis stress response, circadian rhythm research.
Also known as: Nicotinamide Adenine Dinucleotide · NAD
Mechanism of Action
Essential coenzyme in cellular redox reactions — serves as a substrate for sirtuins (SIRT1-7), PARP enzymes, and CD38, regulating mitochondrial biogenesis, DNA repair, and circadian clock function.
Research Focus
Sirtuin activation, mitochondrial biogenesis, DNA repair, cellular aging, metabolic homeostasis.
Also known as: Mitochondrial ORF of the 12S rRNA type-c
Mechanism of Action
Mitochondria-derived peptide encoded in the 12S rRNA gene — translocates to the nucleus under metabolic stress to activate AMPK, regulate AICAR-dependent pathways, and promote mitochondrial biogenesis.
Research Focus
Mitochondrial signaling, AMPK activation, insulin sensitivity, exercise mimetics, longevity research.
Also known as: 5-Amino-1-methylquinolinium
Mechanism of Action
Small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor — blocks NNMT-mediated NAD+ consumption to increase intracellular NAD+ availability and activate sirtuin-dependent metabolic pathways.
Research Focus
NNMT inhibition, NAD+ metabolism, adipogenesis, obesity research, metabolic syndrome models.
Also known as: GH fragment 176-191 · hGH frag 176-191
Mechanism of Action
Modified C-terminal fragment of human growth hormone (residues 176-191) — stimulates lipolysis and inhibits lipogenesis via beta-3 adrenergic receptor activation without affecting IGF-1 or insulin levels.
Research Focus
Lipolysis, fat metabolism, adipose tissue biology, metabolic research without GH receptor activation.
Also known as: Copper tripeptide · Glycyl-L-histidyl-L-lysine copper
Mechanism of Action
Naturally occurring copper-binding tripeptide — activates over 4,000 genes involved in tissue remodeling, upregulates collagen and elastin synthesis, and modulates TGF-beta and VEGF signaling.
Research Focus
Tissue remodeling, collagen synthesis, wound healing, anti-inflammatory gene expression, skin biology.
Mechanism of Action
Research peptide studied for metabolic regulatory properties and energy homeostasis in controlled laboratory settings.
Research Focus
Metabolic regulation, energy homeostasis, longevity pathway research.
Also known as: alpha-MSH C-terminal tripeptide
Mechanism of Action
C-terminal tripeptide of alpha-MSH (Lys-Pro-Val) — activates MC1R and MC3R to suppress NF-κB-mediated inflammatory signaling and reduce pro-inflammatory cytokine production.
Research Focus
Anti-inflammatory signaling, NF-κB pathway, gut inflammation models, MC receptor pharmacology.
Also known as: Long R3 IGF-1 · Insulin-like Growth Factor 1 LR3
Mechanism of Action
Long-acting synthetic analog of IGF-1 with an Arg substitution at position 3 and N-terminal 13-amino acid extension — reduces IGFBP binding affinity by 1000-fold, extending half-life to ~20 hours.
Research Focus
IGF-1 receptor pharmacology, muscle protein synthesis, cell proliferation, anabolic signaling research.
Also known as: Human Chorionic Gonadotropin
Mechanism of Action
Glycoprotein hormone that mimics LH — binds LH/hCG receptors on Leydig cells and granulosa cells to stimulate steroidogenesis and support corpus luteum function.
Research Focus
LH receptor pharmacology, steroidogenesis, reproductive endocrinology, HPG axis research.
Also known as: GSH · gamma-glutamylcysteinylglycine
Mechanism of Action
Endogenous tripeptide antioxidant — serves as the primary intracellular reducing agent, substrate for glutathione peroxidase and S-transferase enzymes, and regulator of redox-sensitive signaling pathways.
Research Focus
Oxidative stress, cellular antioxidant defense, detoxification pathways, redox biology.
Also known as: TH9507 · GHRH analog
Mechanism of Action
Synthetic GHRH analog with a trans-3-hexenoic acid modification — binds GHRH receptors with high affinity and stimulates pulsatile GH secretion with greater stability than native GHRH.
Research Focus
GHRH receptor pharmacology, visceral adiposity research, GH/IGF-1 axis, lipodystrophy models.
Also known as: CJC/Ipa blend · GHRH + GHSR combination
Mechanism of Action
Dual-pathway GH secretagogue combination — CJC-1295 (No DAC) activates GHRH receptors while Ipamorelin activates GHSR-1a, producing synergistic pulsatile GH release 3–5x greater than either compound alone.
Research Focus
Synergistic GH secretagogue pharmacology, dual-pathway pituitary stimulation, GH pulse amplitude.
Mechanism of Action
Proprietary multi-peptide blend formulated for advanced research applications targeting cellular and structural research pathways.
Research Focus
Multi-peptide synergy, cellular research, structural biology applications.
Also known as: BAC water · 0.9% benzyl alcohol water
Mechanism of Action
Sterile, non-pyrogenic diluent containing 0.9% benzyl alcohol — the benzyl alcohol acts as a bacteriostatic preservative, allowing multi-dose use of reconstituted peptide solutions.
Research Focus
Peptide reconstitution, lyophilized compound preparation, sterile diluent for research applications.
This compound index provides mechanism-level reference data for every research peptide in the Aldera Bio Labs catalog. Each entry includes receptor targets, signaling pathways, and primary research applications — sourced from peer-reviewed literature. All compounds are supplied in lyophilized form with third-party COA documentation.
Every compound listed here meets a minimum 99%+ purity standard, independently verified by Horizon Analytical using HPLC and LC-MS. Batch-specific COAs are published in our public COA Vault and linked on every product page. All compounds are lyophilized and fulfilled from our USA-based facility.
For laboratory research use only. All compounds are sold exclusively for in-vitro research by qualified professionals. Not for human consumption. Not FDA-approved. Must be 21 years of age or older to purchase.
